Archive - June 2022
US FDA Accepts for Review Biohaven’s New Drug Application (NDA) Filing of Intranasal Zavegepant for the Treatment of Migraine
Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102
Phathom Pharmaceuticals Announces FDA Acceptance for Filing of Vonoprazan NDA for the Treatment of Erosive Esophagitis
Reata Pharmaceuticals Announces FDA Filing Acceptance and Priority Review Designation for the NDA for Omaveloxolone for the Treatment of Patients with Friedreich’s Ataxia
Amylyx Pharmaceuticals Receives Notification of PDUFA Date Extension for AMX0035 for the Treatment of ALS
Mallinckrodt Announces Resubmission of Terlipressin to the FDA for the Treatment of Hepatorenal Syndrome
Long COVID Could Be Behind Unexplained Hepatitis Cases In Children
U.S. Issues New Warnings On ‘Forever Chemicals’ In Drinking Water
